Skip to main content

Advertisement

Log in

Loss of Interleukin-17RA Expression is Associated with Tumour Progression in Colorectal Carcinoma

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

Interleukin-17 (IL-17) is a pro-inflammatory cytokine found in various cancers. Current evidence indicates that IL-17 plays a vital role in tumour initiation and progression in colorectal carcinoma (CRC) via binding with its receptor, IL-17RA. However, the association between clinicopathological features and presence of IL-17 and IL-17RA protein in primary CRC tissues remains unclear. This study also investigates the difference between the presence of IL-17 and IL-17RA in the paired tumour tissues versus adjacent normal tissues. The presence of IL-17RA and IL-17 protein in primary CRC tissues was determined by immunohistochemistry. Associations between clinicopathological features and IL-17RA and IL-17 immunoreactivity, were analyzed by χ2 tests. We found that both IL-17RA (p = 0.001) and IL-17 (p = 0.025) in tumour cells of primary CRC tissues was significantly lower as compared to adjacent normal tissue. Positive immunoreactivity for IL-17RA and IL-17 were detected in 51.0% and 16.8% of tumour tissues, respectively. Furthermore, negative immunoreactivity of IL-17R was significantly associated with advanced stage according to TNM classifier (p = 0.027), high grade of tumour (p = 0.019), increased depth of tumour invasion (p = 0.023) and vascular invasion (p = 0.039). Positive IL-17 immunoreactivity was associated with advanced stage (p = 0.008) and lymph node metastasis (p = 0.008). Thus, this study suggests that the loss of IL-17RA expression occurs as tumour progresses and this may predict the aggressiveness of tumour whilst expression of IL-17 promotes tumour progression and lymph node metastasis. Thus, loss of IL-17RA could be a useful prognostic biomarker for tumour progression in CRC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Erreni M, Mantovani A, Allavena P (2011) Tumor-associated Macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron 4(2):141–154. https://doi.org/10.1007/s12307-010-0052-5

    Article  CAS  PubMed  Google Scholar 

  2. Pernot S, Terme M, Voron T, Colussi O, Marcheteau E, Tartour E, Taieb J (2014) Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol 20(14):3738–3750. https://doi.org/10.3748/wjg.v20.i14.3738

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D (2013) A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 19(5):619–625. https://doi.org/10.1038/nm.3175

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Misiakos EP, Karidis NP, Kouraklis G (2011) Current treatment for colorectal liver metastases. World J Gastroenterol 17(36):4067–4075. https://doi.org/10.3748/wjg.v17.i36.4067

    Article  PubMed  PubMed Central  Google Scholar 

  5. Jin W, Dong C (2013) IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect. 2. https://doi.org/10.1038/emi.2013.58

  6. Punt S, Langenhoff JM, Putter H, Fleuren GJ, Gorter A, Jordanova ES (2015) The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review. Oncoimmunology 4(2):1–10. https://doi.org/10.4161/2162402X.2014.984547

    Article  CAS  Google Scholar 

  7. Wu D, Wu P, Huang Q, Liu Y, Ye J, Huang J (2013) Interleukin-17: a promoter in colorectal cancer progression. Clin Dev Immunol. 2013:436307. https://doi.org/10.1155/2013/436307

  8. Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, Lin Z, Zhu B (2011) IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 407(2):348–354. https://doi.org/10.1016/j.bbrc.2011.03.021

    Article  CAS  PubMed  Google Scholar 

  9. Yu JJ, Gaffen SL (2008) Interleukin-17: a novel inflammatory cytokine that bridges innate and adaptive immunity. Front Biosci 13(13):170–177. https://doi.org/10.2741/2667

    Article  CAS  PubMed  Google Scholar 

  10. Gu C, Wu L, Li X (2013) Cytokine IL-17 family: cytokines, receptors and signaling. Cytokine 64(2):477–485. https://doi.org/10.1016/j.cyto.2013.07.022

  11. Song X, Qian Y (2013) IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases. Cell Signal 25(12):2335–2347. https://doi.org/10.1016/j.cellsig.2013.07.021

    Article  CAS  PubMed  Google Scholar 

  12. Fabre J, Giustiniani J, Garbar C, Antonicelli F, Merrouche Y, Bensussan A, Bagot M, Al-Dacak R (2016) Targeting the tumor microenvironment: The protumor effects of IL-17 related to cancer type. Int J Mol Sci 17(9). https://doi.org/10.3390/ijms17091433

  13. Doroudchi M, Pishe ZG, Malekzadeh M, Golmoghaddam H, Taghipour M, Ghaderi A (2013) Elevated Serum IL-17A but not IL-6 in glioma versus meningioma and schwannoma. Asian Pac J Cancer Prev 14(9):5225–5230. https://doi.org/10.7314/apjcp.2013.14.9.5225

    Article  PubMed  Google Scholar 

  14. Pan B, Shen J, Cao J, Zhou Y, Shang L, Jin S, Cao S, Che D, Liu F, Yu Y (2015) Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci Rep. 2015. https://doi.org/10.1038/srep16053

  15. Cui G, Yuan A, Goll R, Florholmen J (2012) IL-17A in the tumor microenvironment of the human colorectal adenoma-carcinoma sequence. Scand J Gastroenterol 47(11):1304–1312. https://doi.org/10.3109/00365521.2012.725089

    Article  CAS  PubMed  Google Scholar 

  16. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ (2003) Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 56(3):171–182. https://doi.org/10.1002/pros.10238

    Article  CAS  PubMed  Google Scholar 

  17. Murugaiyan G, Saha B (2009) Protumor vs antitumor functions of IL-17. J Immunol 183(7):4169–4175. https://doi.org/10.4049/jimmunol.0901017

    Article  CAS  PubMed  Google Scholar 

  18. Yang JZ, Li Y, Sun LX, Fang J, Kong LJ, Zhang JQ (2014) Interleukin-17 receptor expression on vascular endothelial cells of masses of skeletal extramedullary disease in myeloma patients. Pathol Res Pract 210(9):586–590. https://doi.org/10.1016/j.prp.2014.04.018

    Article  CAS  PubMed  Google Scholar 

  19. Ibrahim S, Girault A, Ohresser M, Lereclus E, Paintaud G, Lecomte T, Raoul W (2018) Monoclonal antibodies targeting the IL-17/IL-17RA axis: an opportunity to improve the efficiency of anti-VEGF therapy in fighting metastatic colorectal cancer? Clin Colorectal Cancer 17(1):e109–e113. https://doi.org/10.1016/j.clcc.2017.10.003

  20. Razi S, BaradaranNoveiry B, Keshavarz-Fathi M, Rezaei N (2019) IL-17 and colorectal cancer: From carcinogenesis to treatment. Cytokine 116:7–12. https://doi.org/10.1016/j.cyto.2018.12.021

    Article  CAS  PubMed  Google Scholar 

  21. Yang B, Kang H, Fung A, Zhao H, Wang T, Ma D (2014) The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm. 2014:. https://doi.org/10.1155/2014/623759

  22. Amicarella F, Muraro MG, Hirt C, Cremonesi E, Padovan E, Mele V, Governa V, Han J, Huber X, Droeser RA, Zuber M, Adamina M, Bolli M, Rosso R, Lugli A, Zlobec I, Terracciano L, Tornillo L, Zajac P, Eppenberger-Castori S, Trapani F, Oertli D, Iezzi G.(2017). Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. 66:692–704. https://doi.org/10.1136/gutjnl-2015-310016

  23. Wu Z, He D, Zhao S, Wang H (2019) IL-17A/IL-17RA promotes invasion and activates MMP-2 and MMP-9 expression via p38 MAPK signaling pathway in non-small cell lung cancer. 455(1–2):195–206. https://doi.org/10.1007/s11010-018-3483-9

  24. Ernst M, Putoczki T (2014) IL-17 Cuts to the Chase in Colon Cancer. Immunity 41(6):880–882. https://doi.org/10.1016/j.immuni.2014.12.004

    Article  CAS  PubMed  Google Scholar 

  25. Moseley TA, Haudenschild DR, Rose L, Reddi AH (2003) Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14(2):155–174. https://doi.org/10.1016/S1359-6101(03)00002-9

    Article  CAS  PubMed  Google Scholar 

  26. Liu Y, Zhao X, Sun X, Li Y, Wang Z, Jiang J, Han H, Shen W, Corrigan CJ, Sun Y (2015) Expression of IL-17A, E, and F and their receptors in human prostatic cancer: comparison with benign prostatic hyperplasia. Prostate 75(16):1844–1856. https://doi.org/10.1002/pros.23058

    Article  CAS  PubMed  Google Scholar 

  27. Li YX, Zhang L, Simayi D, Zhang N, Tao L, Yang L (2015) Human papilloma virus infection correlates with inflammatory Stat3 signaling activity and IL-17 level in patients with colorectal cancer. 10(2):e0118391. https://doi.org/10.1371/journal.pone.0118391

  28. Jiang Y, Li P, Yang S, Hao Y, Yu P (2015) Increased chemokine receptor IL-17RA expression is associated with poor survival in gastric cancer patients. 8(6):7002–7008

  29. Wang M, Wang L, Ren T, Xu L, Wen Z (2013) IL-17A/IL-17RA interaction promoted metastasis of osteosarcoma cells. Cancer Biol Ther 14(2):155–163. https://doi.org/10.4161/cbt.22955

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yan C, Huang WY, Boudreau J, Mayavannan A, Cheng Z, Wang J (2019) IL-17R deletion predicts high-grade colorectal cancer and poor clinical outcomes. Int J Cancer 145(2):548–558. https://doi.org/10.1002/ijc.32122

    Article  CAS  PubMed  Google Scholar 

  31. Fujii T, Sutoh T, Morita H, Yajima R, Yamaguchi S, Tsutsumi S, Asao T, Kuwano H (2014) Vascular invasion, but not lymphatic invasion, of the primary tumor is a strong prognostic factor in patients with colorectal cancer. Anticancer Res 34(6):3147–3152

    PubMed  Google Scholar 

  32. Xie Z, Qu Y, Leng Y, Sun W, Ma S, Wei J, Hu J, Zhang X (2015) Human colon carcinogenesis is associated with increased interleukin-17-driven inflammatory responses. Drug Des Devel Ther 9:1679–1689. https://doi.org/10.2147/DDDT.S79431

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wu D, Wu P, Huang Q, Liu Y, Ye J, Huang J (2013) Interleukin-17: a promoter in colorectal cancer progression. Clin Dev Immunol. 2013:436307. https://doi.org/10.1155/2013/436307

  34. Tseng JY, Yang CY, Liang SC, Liu RS, Yang SH, Lin JK, Chen YM, Wu YC, Jiang JK, Lin CH (2014) Interleukin-17A modulates circulating tumor cells in tumor draining vein of colorectal cancers and affects metastases. Clin Cancer Res 20(11):2885–2897. https://doi.org/10.1158/1078-0432.CCR-13-2162

    Article  CAS  PubMed  Google Scholar 

  35. Lin Y, Xu J, Su H, Zhong W, Yuan Y, Yu Z, Fang Y, Zhou H, Li C, Huang K (2015) Interleukin-17 is a favorable prognostic marker for colorectal cancer. Clin Transl Oncol 17(1):50–56. https://doi.org/10.1007/s12094-014-1197-3

    Article  CAS  PubMed  Google Scholar 

  36. Qiu L, He D, Fan X, Li Z, Liao C, Zhu Y, Wang H (2011) The expression of interleukin (IL)-17 and IL-17 receptor and MMP-9 in human pituitary adenomas. Pituitary 14(3):266–275. https://doi.org/10.1007/s11102-011-0292-5

    Article  CAS  PubMed  Google Scholar 

  37. Rizzo A, Pallone F, Monteleone G, Fantini MC (2011) Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol. 14;17(26):3092 – 100. https://doi.org/10.3748/wjg.v17.i26.3092

  38. Chow MT, Möller A, Smyth MJ (2012) Inflammation and immune surveillance in cancer. Semin Cancer Biol 22(1):23–32. https://doi.org/10.1016/j.semcancer.2011.12.004

    Article  CAS  PubMed  Google Scholar 

  39. Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J (2014) Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol 5:75. https://doi.org/10.3389/fphys.2014.00075

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Heng Fong Seow.

Ethics declarations

Conflict of Interest

These authors disclose no conflicts of interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chai, B., Yip, W.K., Dusa, N. et al. Loss of Interleukin-17RA Expression is Associated with Tumour Progression in Colorectal Carcinoma. Pathol. Oncol. Res. 26, 2291–2298 (2020). https://doi.org/10.1007/s12253-020-00820-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-020-00820-4

Keywords

Navigation